One CSL CSL is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000+ people. Employees North America 19,189 59% Europe, Middle East, Africa (EMEA) 8,075 25% Australia and New Zealand 3,107 9% United Kingdom 1,093 3% Asia 1,004 3% South America 230 1% Global presence CSL Behring & CSL R&D Australia China Germany Switzerland United States CSL Seqirus & CSL R&D United Kingdom United States CSL Vifor & CSL R&D Switzerland CSL Plasma China Germany Hungary Puerto Rico United States CSL Vifor Switzerland CSL Seqirus Australia United Kingdom CSL R&D Australia China Italy Japan Netherlands Spain United Kingdom United States Regional Sales and/or Distribution Head Office Melbourne, Australia US$2.64 dividend per share for 2024 100+ countries that CSL provides lifesaving products to patients US$5.8b in R&D investments in the last 5 years to advance CSL’s product pipeline 110 million influenza doses distributed in FY24 US$14.8b in annual revenue 349 plasma collection centres across China, Europe and North America 32,000+ globally 2 Limited Annual Report 2023/24
RkJQdWJsaXNoZXIy MjE2NDg3